Stock_Titan Posted - 3 days ago

$KRMD KORU Medical Systems Signs Supply Agreement for a Phase III Clinical Trial for a Novel Endocrinological Biologic https://www.stocktitan.net/news/KRMD/koru-medical-systems-signs-supply-agreement-for-a-phase-iii-clinical-t3nctlf43505.html

copywrites Posted - 4 days ago

$KRMD high Volume today 🧐

Stock_Titan Posted - 2 weeks ago

$KRMD KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth https://www.stocktitan.net/news/KRMD/koru-medical-systems-inc-announces-2024-first-quarter-financial-d4w8460g5k81.html

Stock_Titan Posted - 1 month ago

$KRMD KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024 https://www.stocktitan.net/news/KRMD/koru-medical-systems-to-report-first-quarter-2024-financial-results-utaf0r2rh291.html

Dusty_Bunz Posted - 1 month ago

$KRMD

GoGreen21 Posted - 1 month ago

$KRMD Linda Tharby Chief Executive Officer and President, Director since 2022 Ms. Tharby has served as the Company’s Chief Executive Officer since April 2021. Ms. Tharby has over 25 years of executive leadership experience building and leading strong performing global organizations that develop and commercialize products and service innovations, while delivering solutions to patients in the home setting. Prior to joining the Company, Ms. Tharby spent the last 24 years working in various roles of increased responsibility at Becton Dickinson (“BD”). Ms. Tharby was a member of the Executive Leadership team of BD that transformed the company from an $8 billion medical supplies company to an $18 billion global medical technology company.

Stock_Titan Posted - 1 month ago

$KRMD KORU Medical Systems Announces Successful Appeal in EU Notified Body Review https://www.stocktitan.net/news/KRMD/koru-medical-systems-announces-successful-appeal-in-eu-notified-body-iho09hvg82m9.html

Monster_Mover_Stocks Posted - 1 month ago

Top 3 sub $10 end of after-hours trading low float volume buzz leaders: $HWH $PIK $KRMD

Catspaw1 Posted - 03/29/24

$KRMD Should see 3.50 again soon

davemn Posted - 03/21/24

$KRMD price follows the revenue growth very closely. Should be a good Q1 earnings and further out comps in 24, leading to an impressive 2025 - 25+% growth rate. Given that they execute: 2024 5X EV/sales ~$4 2025 10X EV/sales ~$9 Lots of $$ on the sidelines waiting for rate cuts .. Small cap GROWTH stock that is PROFITABLE & ZERO debt!

Stock_Titan Posted - 1 month ago

$KRMD KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference https://www.stocktitan.net/news/KRMD/koru-medical-systems-to-present-data-demonstrating-97-adherence-on-7u1bxdyxmjvn.html

investawaymillions Posted - 2 months ago

$KRMD Morning pump 8% followed by whale sale. Spoofing...

davemn Posted - 2 months ago

$KRMD 3/14 KRMD Analyst Updates: Lake Street - Buy $4.00 B. Riley - Buy $4.00 Craig-Hallum - Buy (no PT but last I recall was $6.00) Piper Sandler - Buy $2.50 Canaccord - Buy $3.00

Thestocktraderhubzee Posted - 2 months ago

$KRMD B. Riley Securities Reiterates Buy on KORU Medical Systems, Maintains $4 Price Target

DonCorleone77 Posted - 2 months ago

$KRMD Koru Medical sees FY24 revenue $31.2M-$32.2M, consensus $32.26M Sees FY24 gross margin 59%-61%.

DonCorleone77 Posted - 2 months ago

$KRMD Koru Medical reports Q4 adjusted EPS (2c), consensus (4c) Reports Q4 revenue $7.2M, consensus $6.94M. "I am proud of the KORU team for delivering a solid end to 2023, led by performance in our Core business. Entry into multiple geographic markets drove international sales, and in the US, we hit a key milestone with the FDA clearance and launch of the 50mL prefill pump platform, which we anticipate will be a significant growth driver in 2024. Additionally, we saw double-digit growth in our end-user specialty pharmacy sales, reflective of share gains and a growing Ig market," said Linda Tharby, KORU Medical's President and CEO. "Within our Novel Therapies business, we recently announced collaborations for two late-stage therapies. On the operational side, we increased gross margins, were cash flow positive in the fourth quarter and finished the year with a significantly lower cash burn than the prior year...."

Stock_Titan Posted - 2 months ago

$KRMD KORU Medical Systems, Inc. Announces 2023 Fourth Quarter, Full Year Financial Results, and 2024 Guidance https://www.stocktitan.net/news/KRMD/koru-medical-systems-inc-announces-2023-fourth-quarter-full-year-g19yfqric93k.html

davemn Posted - 2 months ago

$KRMD newest release is likely for UCB's Rystiggo. Less about the drug and more about entering a new drug delivery setting where there is huge opportunity. Looking forward to earnings tomorrow as they just keep plugging along.

Stock_Titan Posted - 2 months ago

$KRMD KORU Medical Systems Announces a Feasibility Study to Enter Ambulatory Infusion Settings with a Commercialized Biologic https://www.stocktitan.net/news/KRMD/koru-medical-systems-announces-a-feasibility-study-to-enter-kmehhomrbr2e.html

OpenOutcrier Posted - 2 months ago

$KRMD (+7.8% pre) Repro Med Systems (KRMD) Enters Clinical Supply Agreement for Phase 3 Trial with Leading Pharma Partner - SI https://ooc.bz/l/27115

Stock_Titan Posted - 2 months ago

$KRMD KORU Medical Systems Signs a Clinical Supply Agreement for Phase 3 Trial with Leading Pharma Partner Using Custom Device for a Novel Subcutaneous Immunoglobulin https://www.stocktitan.net/news/KRMD/koru-medical-systems-signs-a-clinical-supply-agreement-for-phase-3-47z73b67rsna.html

Stock_Titan Posted - 02/21/24

$KRMD KORU Medical Systems to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024 https://www.stocktitan.net/news/KRMD/koru-medical-systems-to-report-fourth-quarter-and-full-year-2023-rcjv7963ka3w.html

davemn Posted - 3 months ago

$KRMD CSL half year update is available. A few Highlights: -Ig growth overall +23% -Hizentra growth +18% -Focus to transition from IV to SQ as part of margin improvement strategy - Hizentra >> Privigen -Phase3 data for DM (Hizentra) in Q3, orphan drug status -50mL prefilled syringe launched I would guess that with the recent failure of Apolipoprotein A-I, CSL Behring's largest drug trial, there will be even more focus on Ig, more specifically SQ Hizentra, to carry the revenue growth. KRMD is well positioned!

investawaymillions Posted - 3 months ago

$KRMD CFO was only at the Company for one month and left...

CrayP Posted - 3 months ago

$KRMD On the next installment of Between Two Ferns....

davemn Posted - 01/31/24

$KRMD sooner than later they have to announce news. One-third of the pipeline is in Oncology and >60% is in Phase 3. Cash flow breakeven this year, 2X revenue by 2026 and +10% EBITDA margins. My #1 pick over the next 12-24 months.

Catspaw1 Posted - 4 months ago

$KRMD Manko still owns 7,781,332 shares. If I understand the filing correctly he just moved those 453,231 shares to a private trust. Value of transaction was 0.

cctranscripts Posted - 4 months ago

REPRO MED SYSTEMS INC insider just disposed of 453,231 shares https://www.conferencecalltranscripts.org/summary/?id=12863893 $KRMD

investawaymillions Posted - 4 months ago

$KRMD Why would Horton sell 1.5 million shares?

davemn Posted - 4 months ago

$KRMD CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe. "According to a Harris Poll survey of 100 adults living with CIDP, 72% said that administering treatment at home is extremely/very important to them. In a separate survey of 52 people living with PI who have used both SCIg and intravenous immunoglobulin treatment (IVIg), almost 80% said they preferred SCIg over IVIg"